Mark Neumann - Oct 15, 2021 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
EVP, Chief Commercial Officer
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Stock symbol
ITCI
Transactions as of
Oct 15, 2021
Transactions value $
-$549,551
Form type
4
Date filed
10/19/2021, 04:26 PM
Next filing
Jan 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +13.4K +29.66% 58.8K Oct 15, 2021 Direct F1
transaction ITCI Common Stock Sale -$278K -6.7K -11.4% $41.49 52.1K Oct 18, 2021 Direct F2, F3
transaction ITCI Common Stock Sale -$175K -4.29K -8.23% $40.77 47.8K Oct 18, 2021 Direct F2, F4
transaction ITCI Common Stock Sale -$77.2K -1.96K -4.1% $39.44 45.8K Oct 18, 2021 Direct F2, F5
transaction ITCI Common Stock Sale -$19.4K -500 -1.09% $38.88 45.3K Oct 18, 2021 Direct F2, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -13.4K -100% $0.00* 0 Oct 15, 2021 Common Stock 13.4K Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2021. A substantial portion of the proceeds from these sales will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.04 to $42.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.34 to $41.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.60 to $39.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7 Each restricted stock unit represents a contingent right to receive one share of common stock.
F8 The restricted stock units vest as to one third of the shares on October 15, 2019, one third of the shares on October 15, 2020 and one third of the shares on October 15, 2021.